The abstract is read at the publisher; the summary is JClub's.
Whole-genome sequencing across 17,029 solid tumours identified immediately actionable alterations in 18.9% of UK primary cancers and 25.9% of Netherlands metastatic cancers.
- Why it matters: Precision oncology is limited because targeted therapies are approved only for tumour types with frequent, highly specific mutations, leaving many potential vulnerabilities uncharacterized.
- What they did: In a retrospective pan-solid analysis, matched tumour–normal DNA underwent whole-genome sequencing in 11,013 primary tumours from the UK 100k Genomes Project and 6,016 metastatic tumours from the Hartwig Medical Foundation.
- The result: Beyond immediately actionable events, 10.9% of primary and 14.4% of metastatic cancers also had investigational or mutational signature-informed features, including many in tumour types lacking FDA-approved biomarkers.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.